Roche presents vamikibart data for Roche Holding stock
Published on 10/14/2026 at 13:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRoche advances its eye-care pipeline
- Roche presented 52-week vamikibart data and disclosed an FDA decision target of July 2027 on October 10, 2026.
- Tecentriq reduced recurrence or death risk by 50 percent in the ATOMIC study, reported on October 9, 2026.
- Roche Holding stock was trading at EUR 389.95 at 1:02 p.m. CEST at Lang & Schwarz on October 14, 2026.
- Third-quarter sales are scheduled for October 22, 2026.
Roche Holding (CH1499059983) presented 52-week vamikibart data on October 10, 2026, while the FDA accepted the drug's application for uveitic macular edema. Roche Holding stock was trading at EUR 389.95 at Lang & Schwarz on October 14, 2026 at 1:02 p.m. CEST. The filing carries a possible approval decision by July 2027, giving the pipeline update a concrete regulatory timetable.
Eye drug reaches regulatory stage
According to Roche, the MEERKAT and SANDCAT studies showed sustained improvements in vision and reduced macular thickness after 52 weeks. The company said the FDA had accepted its Biologics License Application, with regulatory submissions also accepted in the European Union, China and Japan.
The commercial significance remains conditional on approval, but the data add a late-stage asset to Roche's ophthalmology pipeline. Roche said two-thirds of eligible patients required no retreatment after 16 weeks, while most patients who received another injection needed only one additional dose.
What does the pipeline mean for growth?
The near-term earnings focus remains the third-quarter sales release. Roche Investor Relations scheduled the release for October 22, 2026 before the Swiss market opens. The presentation is set for 2:00 p.m. CEST that day.
Recent regulatory progress also includes Tecentriq approval in the United States. In its October 9, 2026 release, Roche said the ATOMIC study showed a 50 percent reduction in the risk of recurrence or death compared with chemotherapy alone. The study reported 36-month disease-free survival of 86 percent with Tecentriq and chemotherapy versus 76 percent with chemotherapy alone.
Three recent Roche milestones
On September 22, 2026, Roche scheduled its third-quarter sales presentation for October 22, 2026. On October 9, 2026, the FDA approved Tecentriq for a stage III colon-cancer setting, expanding the medicine to its twelfth US indication. On October 10, 2026, Roche presented 52-week vamikibart data and disclosed FDA filing acceptance.
Upcoming dates for investors
Roche's next scheduled reporting event is third-quarter sales on October 22, 2026, followed by the Berenberg Pharma CFO Series on November 2, 2026, according to the company's investor calendar.
Stock price and reporting date
Roche Holding stock was trading at EUR 389.95 at Lang & Schwarz on October 14, 2026 at 1:02 p.m. CEST. The next company sales update is scheduled for October 22, 2026.
The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.
Roche Holding stock facts
- Company: Roche Holding AG
- ISIN: CH1499059983
- Ticker: ROG
- Primary exchange: SIX Swiss Exchange
- Price Lang & Schwarz (as of October 14, 2026, 1:02 p.m. CEST): EUR 389.95
- Sector: Healthcare
- Market capitalization: CHF 256.6 billion (as of March 16, 2026)
Market context: Market report SMI.
